Iguratimod (IGU), a disease-modifying antirheumatic drug launched in September 2012, has been reported to carry a risk of severe hemorrhages through a suspected interaction with warfarin (WF) in the all-case surveillance and early postmarketing-phase vigilance. To elucidate possible mechanisms of adverse interaction between IGU and WF, we analyzed the eŠects of IGU on the pharmacodynamics and pharmacokinetics of WF in rats. IGU was orally administered to male Wistar rats once daily for 5 d at 10 or 30 mg/kg in combination with WF at an oral dose of 0.25 mg/kg. Coadministration of IGU 30 mg/kg enhanced the anticoagulant activity of WF; prolonged blood coagulation time (prothrombin time and activated partial thromboplastin time) and decreased levels of vitamin K (VK)-dependent blood coagulation factors (II, VII, IX, and X) were observed. On the other hand, the pharmacokinetic parameters of WF including maximum plasma concentration (C max ) and area under the plasma concentration-time curve from 0 to 24 h (AUC 0 24 h ) were not aŠected by the combination with IGU. IGU alone did not change blood coagulation time at doses up to 100 mg/kg, while VK-dependent blood coagulation factors decreased slightly at 30 and 100 mg/kg. These results suggest that the pharmacodynamic eŠect of IGU on VK-dependent blood coagulation factors is involved in the mechanism of drug drug interaction of IGU with WF. 
Table 1. Pharmacokinetic Parameters of S-(-)-warfarin and R-(＋)-warfarin in Combined Administration of Iguratimod or
Fluconazole with Sodium Warfarin in Rats Iguratimod (10 or 30 mg/kg) or ‰uconazole (10 mg/kg) was orally administered once daily for 5 d to Wistar/ST male rats in combination with sodium warfarin (0.25 mg/kg). Plasma was successively collected after the last dosing. Concentrations of S-(-)-and R-(＋)-warfarin were measured using a liquid chromatography-tandem mass spectrometry method. Each pharmacokinetic parameter was represented as the mean±S.D. NS , no signiˆcance vs. WF Na (0.25 mg/ kg) alone group. # p＜0.05 vs. WF Na (0.25 mg/kg) alone group (Student's t-test). C max , maximum plasma concentration; AUC 0 24 h , area under the plasma concentration-time curve from 0 to 24 h; WF Na, sodium warfarin; IGU, iguratimod; FLCZ, ‰uconazole. Table 2 .
EŠect of Iguratimod on Plasma Levels of Blood Coagulation Factors in Rats
Group (mg/kg) n VK-dependent blood coagulation factor VK-independent blood coagulation factor
WF Na (0.
Iguratimod (10, 30, or 100 mg/kg) or sodium warfarin (0.25 mg/kg) was orally administered once daily for 5 d to Wistar/ST male rats. Plasma was collected 4 h after the last dosing, and levels of blood coagulation factors were examined. Data were represented as the percentage±S.D. of each blood coagulation factor level in the control group, which was administered 0.5％ sodium carboxymethyl cellulose and water. VK, vitamin K; IGU, iguratimod; WF Na, sodium warfarin. Table 3 . Combined EŠect of Iguratimod with Sodium Warfarin on Plasma Levels of Blood Coagulation Factors in Rats Group (mg/kg) n VK-dependent blood coagulation factor VK-independent blood coagulation factor
Iguratimod (10 or 30 mg/kg) was orally administered in combination with sodium warfarin (0.25 mg/kg) once daily for 5 d to Wistar/ST male rats. Plasma was collected 4 h after the last dosing, and levels of blood coagulation factors were examined. Each data was represented as the percentage±S.D. of each blood coagulation factor level in the control group, which was administered 0.5％ sodium carboxymethyl cellulose and water. VK, vitamin K; WF Na, sodium warfarin; IGU, iguratimod. 
